Linvoseltamab BLA accepted for Priority Review for R/R multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has accepted for Priority Review the biologics license application for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma that has progressed after at least three prior therapies. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login